Pacific Biosciences of California (PACB) Competitors $1.76 +0.03 (+1.44%) As of 03:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PACB vs. TXG, HBIO, TMO, A, MTD, WAT, ILMN, TECH, CRL, and BIOShould you be buying Pacific Biosciences of California stock or one of its competitors? The main competitors of Pacific Biosciences of California include 10x Genomics (TXG), Harvard Bioscience (HBIO), Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Bio-Techne (TECH), Charles River Laboratories International (CRL), and Bio-Rad Laboratories (BIO). Pacific Biosciences of California vs. Its Competitors 10x Genomics Harvard Bioscience Thermo Fisher Scientific Agilent Technologies Mettler-Toledo International Waters Illumina Bio-Techne Charles River Laboratories International Bio-Rad Laboratories 10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends. Does the media favor TXG or PACB? In the previous week, 10x Genomics had 16 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 21 mentions for 10x Genomics and 5 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 0.79 beat Pacific Biosciences of California's score of 0.35 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacific Biosciences of California 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, TXG or PACB? 10x Genomics has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Pacific Biosciences of California has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500. Which has preferable valuation and earnings, TXG or PACB? 10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio10x Genomics$610.78M2.50-$182.63M-$0.70-17.53Pacific Biosciences of California$154.01M3.44-$309.85M-$2.29-0.77 Do analysts recommend TXG or PACB? 10x Genomics presently has a consensus price target of $13.65, suggesting a potential upside of 11.27%. Pacific Biosciences of California has a consensus price target of $1.90, suggesting a potential upside of 7.65%. Given 10x Genomics' stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Pacific Biosciences of California.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 10x Genomics 2 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.38Pacific Biosciences of California 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Is TXG or PACB more profitable? 10x Genomics has a net margin of -13.13% compared to Pacific Biosciences of California's net margin of -336.40%. 10x Genomics' return on equity of -12.88% beat Pacific Biosciences of California's return on equity.Company Net Margins Return on Equity Return on Assets 10x Genomics-13.13% -12.88% -10.03% Pacific Biosciences of California -336.40%-66.75%-16.90% Do institutionals & insiders hold more shares of TXG or PACB? 84.7% of 10x Genomics shares are held by institutional investors. 9.4% of 10x Genomics shares are held by company insiders. Comparatively, 2.5% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Summary10x Genomics beats Pacific Biosciences of California on 14 of the 17 factors compared between the two stocks. Get Pacific Biosciences of California News Delivered to You Automatically Sign up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PACB vs. The Competition Export to ExcelMetricPacific Biosciences of CaliforniaMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$530.15M$7.04B$6.14B$10.45BDividend YieldN/A1.18%5.73%4.78%P/E Ratio-0.7726.8785.0627.10Price / Sales3.4428.54570.65176.64Price / CashN/A21.7037.3961.86Price / Book0.955.1712.406.66Net Income-$309.85M$178.09M$3.32B$276.79M7 Day Performance15.36%-3.08%-0.23%-1.40%1 Month Performance43.50%4.61%9.56%5.64%1 Year Performance-14.32%3.23%71.76%37.04% Pacific Biosciences of California Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PACBPacific Biosciences of California1.0312 of 5 stars$1.77+1.4%$1.90+7.6%-17.1%$530.15M$154.01M-0.77730TXG10x Genomics3.8189 of 5 stars$11.60+1.1%$13.65+17.7%-25.3%$1.44B$610.78M-16.571,240Trending NewsAnalyst ForecastAnalyst RevisionHBIOHarvard Bioscience4.3003 of 5 stars$0.42+0.5%$2.00+374.3%-82.7%$18.78M$94.14M-0.32490TMOThermo Fisher Scientific4.8791 of 5 stars$524.80flat$593.43+13.1%-12.2%$198.17B$42.88B30.35125,000Trending NewsUpcoming EarningsAnalyst ForecastAnalyst RevisionGap UpAAgilent Technologies4.5529 of 5 stars$138.43+1.3%$148.69+7.4%-3.8%$39.24B$6.79B32.4917,900Analyst ForecastAnalyst RevisionMTDMettler-Toledo International3.9098 of 5 stars$1,289.13+1.2%$1,336.50+3.7%-10.3%$26.56B$3.87B32.6417,300Positive NewsWATWaters4.4059 of 5 stars$336.83+1.8%$377.56+12.1%-7.5%$20.05B$2.96B30.377,600ILMNIllumina4.7886 of 5 stars$95.03+1.2%$123.56+30.0%-37.0%$14.61B$4.28B12.039,030Trending NewsAnalyst RevisionTECHBio-Techne4.6952 of 5 stars$59.65+1.7%$70.17+17.6%-19.0%$9.29B$1.22B129.683,100Trending NewsAnalyst ForecastAnalyst RevisionCRLCharles River Laboratories International4.1065 of 5 stars$170.85+2.3%$179.93+5.3%-11.8%$8.41B$4.03B-128.4620,100News CoverageAnalyst UpgradeAnalyst RevisionBIOBio-Rad Laboratories4.0884 of 5 stars$303.56+2.0%$333.50+9.9%-10.7%$8.21B$2.57B25.887,700News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies TXG Competitors HBIO Competitors TMO Competitors A Competitors MTD Competitors WAT Competitors ILMN Competitors TECH Competitors CRL Competitors BIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PACB) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacific Biosciences of California, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacific Biosciences of California With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
